ABOS
Price
$1.00
Change
-$0.08 (-7.41%)
Updated
Apr 3, 02:26 PM (EDT)
Capitalization
65.42M
47 days until earnings call
BEAM
Price
$16.91
Change
-$1.57 (-8.50%)
Updated
Apr 3, 02:30 PM (EDT)
Capitalization
1.85B
40 days until earnings call
Ad is loading...

ABOS vs BEAM

Header iconABOS vs BEAM Comparison
Open Charts ABOS vs BEAMBanner chart's image
Acumen Pharmaceuticals
Price$1.00
Change-$0.08 (-7.41%)
Volume$100
Capitalization65.42M
Beam Therapeutics
Price$16.91
Change-$1.57 (-8.50%)
Volume$1.24K
Capitalization1.85B
ABOS vs BEAM Comparison Chart
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABOS vs. BEAM commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and BEAM is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ABOS: $1.08 vs. BEAM: $18.48)
Brand notoriety: ABOS and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 89% vs. BEAM: 108%
Market capitalization -- ABOS: $65.42M vs. BEAM: $1.85B
ABOS [@Biotechnology] is valued at $65.42M. BEAM’s [@Biotechnology] market capitalization is $1.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 4 bullish TA indicator(s).

  • ABOS’s TA Score: 4 bullish, 4 bearish.
  • BEAM’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than BEAM.

Price Growth

ABOS (@Biotechnology) experienced а -6.90% price change this week, while BEAM (@Biotechnology) price change was -15.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.56%. For the same industry, the average monthly price growth was -9.64%, and the average quarterly price growth was -14.03%.

Reported Earning Dates

ABOS is expected to report earnings on May 20, 2025.

BEAM is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-7.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.85B) has a higher market cap than ABOS($65.4M). BEAM YTD gains are higher at: -25.484 vs. ABOS (-37.209). ABOS has higher annual earnings (EBITDA): -77.89M vs. BEAM (-383.98M). BEAM has more cash in the bank: 851M vs. ABOS (200M). ABOS has less debt than BEAM: ABOS (28.5M) vs BEAM (161M). BEAM has higher revenues than ABOS: BEAM (63.5M) vs ABOS (0).
ABOSBEAMABOS / BEAM
Capitalization65.4M1.85B4%
EBITDA-77.89M-383.98M20%
Gain YTD-37.209-25.484146%
P/E RatioN/AN/A-
Revenue063.5M-
Total Cash200M851M24%
Total Debt28.5M161M18%
TECHNICAL ANALYSIS
Technical Analysis
ABOSBEAM
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 4 days ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 7 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PYXS1.020.10
+11.48%
Pyxis Oncology
ONEW17.030.85
+5.25%
OneWater Marine
FN201.884.86
+2.47%
Fabrinet
GES11.380.21
+1.88%
Guess
NVS110.771.16
+1.06%
Novartis AG

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with FHTX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then FHTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+0.47%
FHTX - ABOS
52%
Loosely correlated
+1.33%
ATOS - ABOS
49%
Loosely correlated
+5.62%
ALEC - ABOS
49%
Loosely correlated
+1.72%
GBIO - ABOS
48%
Loosely correlated
+0.57%
BEAM - ABOS
47%
Loosely correlated
+4.79%
More

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+4.79%
CRSP - BEAM
73%
Closely correlated
+3.17%
NTLA - BEAM
62%
Loosely correlated
+9.69%
RXRX - BEAM
62%
Loosely correlated
+3.83%
AXON - BEAM
57%
Loosely correlated
+3.18%
DNLI - BEAM
57%
Loosely correlated
+11.80%
More